Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy
Open Access
- 11 March 2020
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 74 (4) , 1189-1201
Abstract
Background: There is limited data on cerebrospinal fluid (CSF) biomarkers in sporadic amyloid-β (Aβ) cerebral amyloid angiopathy (CAA). Objective: To determine the profile of biomarkers relevant to neurodegenerative disease in the CSF of patients with CAA. Methods: We performed a detailed comparison of CSF markers, comparing patients with CAA, Alzheimer’s disease (AD), and control (CS) participants, recruited from the Biomarkers and Outcomes in CAA (BOCAA) study, and a Specialist Cognitive Disorders Service. Results: We included 10 CAA, 20 AD, and 10 CS participants (mean age 68.6, 62.5, and 62.2 years, respectively). In unadjusted analyses, CAA patients had a distinctive CSF biomarker profile, with significantly lower ( p < 0.01) median concentrations of Aβ 38 , Aβ 40 , Aβ 42 , sAβPP α, and sAβPPβ. CAA patients had higher levels of neurofilament light (NFL) than the CS group ( p < 0.01), but there were no significant differences in CSF total tau, phospho-tau, soluble TREM2 (sTREM2), or neurogranin concentrations. AD patients had higher total tau, phospho-tau and neurogranin than CS and CAA groups. In age-adjusted analyses, differences for the CAA group remained for Aβ 38 , Aβ 40 , Aβ 42 , and sAβPPβ. Comparing CAA patients with amyloid-PET positive ( n = 5) and negative ( n = 5) scans, PET positive individuals had lower ( p < 0.05) concentrations of CSF Aβ 42 , and higher total tau, phospho-tau, NFL, and neurogranin concentrations, consistent with an “AD-like” profile. Conclusion: CAA has a characteristic biomarker profile, suggestive of a global, rather than selective, accumulation of amyloid species; we also provide evidence of different phenotypes according to amyloid-PET positivity. Further replication and validation of these preliminary findings in larger cohorts is needed.Keywords
This publication has 44 references indexed in Scilit:
- Review: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapyNeuropathology and Applied Neurobiology, 2013
- Prevalence of superficial siderosis in patients with cerebral amyloid angiopathyNeurology, 2010
- Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS studyEuropean Journal of Neurology, 2010
- Cerebrospinal fluid and plasma biomarkers in Alzheimer diseaseNature Reviews Neurology, 2010
- Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathyAnnals of Neurology, 2009
- Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric InfarctsEuropean Neurology, 1996
- Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron, 1994
- Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992
- The molecular pathology of Alzheimer's diseaseNeuron, 1991